Ananth has more than 15 years of pharmaceutical consulting experience with expertise in modeling and simulation and its applications, including decision tree, state-transition (i.e., Markov), and discrete event simulation (DES) approaches to health economic modeling. Specifically, he has led the development of cost-effectiveness models for drugs for oncology and cardiovascular indications that were used to support HTA submissions to the National Institute of Clinical Excellence (NICE), and the Canadian Agency for Drugs and Technologies in Health (CADTH), respectively. Among his former industry roles, Ananth was director of modeling and simulation development and a research scientist in Evidera’s modeling and simulation group, where he led cross-functional teams responsible for the development of global cost-effectiveness and budget-impact models in multiple therapeutic areas, economic analyses alongside clinical trials, systematic literature reviews, and complex statistical analyses. He also led the development of initiatives within Evidera on novel simulation techniques, including clinical trial simulation. Ananth was formerly senior vice president, PhysioPD™ at Rosa & Co., LLC, and vice president of R&D at Entelos Inc. In both roles, he held wide-ranging executive management and program leadership responsibilities. Ananth’s scientific expertise includes cardiovascular disease, cancer biology, and inflammation; he has also co-authored many published peer-reviewed manuscripts in life science, modeling, and health economic journals including Clinical Therapeutics, Postgraduate Medicine, Science, Blood, and Cancer Research.
Ananth completed his PhD in biomedical engineering at the University of Virginia, Charlottesville, Virginia, where he focused on the study of inflammation and mammalian vasculature. He then completed two postdoctoral fellowships at Massachusetts General Hospital and the University of California, San Francisco, focusing on oncology.